The research, by Gary Dushnitsky, Associate Professor of Strategy and Entrepreneurship, London Business School and his co-author Dr Alvarez-Garrido, is featured in the British Venture Capital Association’s report ‘The Missing Piece’ and finds that corporate venture capital is now the driving force behind cutting edge medical innovation.
Dr Dushnitsky, also Academic Director, Deloitte Institute for Innovation and Entrepreneurship, said, “Biotech start-ups are increasingly turning to corporate venture capital arms, which are steadily on the rise, while traditional venture capital funds are partially drying out. In a recent Nature Biotechnology study, my co-author and I find that the shift in funding patterns is resulting in an increase in scientific publications as well as patenting output.